M2pep-targeted CSF-1R siRNA cyclodextrin nanoparticles

This experimental nanoparticle-based immunotherapeutic formulation is designed for the treatment of prostate cancer by targeting the tumor microenvironment. It consists of small interfering RNA (siRNA) directed against the colony-stimulating factor-1 receptor (CSF-1R), encapsulated within a delivery system composed of amphiphilic cationic β-cyclodextrin and DSPE-PEG. The nanoparticles are functionalized with M2pep, a peptide that specifically targets M2-polarized tumor-associated macrophages (TAMs). By delivering siRNA to these macrophages, the formulation induces the downregulation of CSF-1R, which is critical for the survival and polarization of M2 macrophages. This leads to the reprogramming of immunosuppressive M2 macrophages into immunostimulatory M1 macrophages, promoting the release of M1-associated cytokines and the recruitment of cytotoxic T cells. Preclinical studies in mouse models of prostate cancer have demonstrated significant antitumor efficacy and remodeling of the tumor microenvironment.

Other names

M2pep-targeted CD-based delivery systemM-2pep-targeted CD-based delivery systemM 2pep-targeted CD-based delivery systemCSF-1R siRNA + cyclodextrin + DSPE-PEGM2 macrophage-targeted cyclodextrin-based nanoparticlesM-2 macrophage-targeted cyclodextrin-based nanoparticlesM 2 macrophage-targeted cyclodextrin-based nanoparticles